To assess the use of a suicide gene and evaluate activation process impact in cells from leukemic donors, RapaCasp9-G-expressing GMTCs were also produced from AML patients with a sufficient transduction efficiency in both IL-2 and IL-7/-15 conditions (Fig. 5B top). This evidence concerns the gene IL7 and acute myeloid leukemia.